HIV/AIDS remains a global health problem that needs to be addressed with basic and applied research Methods developed by Dr. Nussenzweig to isolate large numbers of anti-HIV antibodies from the sera of HIV-infected individuals offers the opportunity for comprehensive structural and functional experiments to study the new antibodies using structural biology, in vitro and in vivo characterizations, and studies of effector functions mediated by Fc receptors. Expression and production of purified proteins, including HIV proteins, Fc receptors, and natural and designed antibodies, is a major component of our program project. Dr. Nussenzweig will need large quantities of purified antibodies as well as gp120s and gp140s designed to be potential immunogens for the in vivo studies proposed in Project 1. Dr. Ravetch will need a panel of HAAD and other anti-HIV antibodies with modified Fc regions and altered glycans for evaluating effector functions in Project 2. Dr. Bjorkman will need large quantities of purified Fabs, Fc receptors, and many forms of gpl20 or gpl40 antigens (including resurfaced gpl20s) for complex formation, crystallization, structure determinations, and immunogen studies in Project 3. The large number of different antibodies, HIV proteins, and Fc receptors to be expressed and purified requires a dedicated protein expression core.

Public Health Relevance

Biochemical, structural, and cellular assays to evaluate a new set of anti-HIV antibodies will require expression of large numbers of proteins, including HIV envelope proteins and antibodies. The Protein Expression Core will provide purified proteins for this program project, which will facilitate the goals of understanding how to elicit broadly neutralizing antibodies with enhanced effector functions, and how to improve them for passive immunization.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RRS-A (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
California Institute of Technology
United States
Zip Code
Wang, Haoqing; Barnes, Christopher O; Yang, Zhi et al. (2018) Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host Microbe 24:579-592.e4
Stadtmueller, Beth M; Bridges, Michael D; Dam, Kim-Marie et al. (2018) DEER Spectroscopy Measurements Reveal Multiple Conformations of HIV-1 SOSIP Envelopes that Show Similarities with Envelopes on Native Virions. Immunity 49:235-246.e4
Gautam, Rajeev; Nishimura, Yoshiaki; Gaughan, Natalie et al. (2018) A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med 24:610-616
Cohn, Lillian B; da Silva, Israel T; Valieris, Renan et al. (2018) Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nat Med 24:604-609
Horwitz, Joshua A; Bar-On, Yotam; Lu, Ching-Lan et al. (2017) Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell 170:637-648.e10
Nishimura, Yoshiaki; Gautam, Rajeev; Chun, Tae-Wook et al. (2017) Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543:559-563
Bournazos, Stylianos; Ravetch, Jeffrey V (2017) Anti-retroviral antibody Fc?R-mediated effector functions. Immunol Rev 275:285-295
Gristick, Harry B; Wang, Haoqing; Bjorkman, Pamela J (2017) X-ray and EM structures of a natively glycosylated HIV-1 envelope trimer. Acta Crystallogr D Struct Biol 73:822-828
Bournazos, Stylianos; Wang, Taia T; Dahan, Rony et al. (2017) Signaling by Antibodies: Recent Progress. Annu Rev Immunol 35:285-311
Bournazos, Stylianos; Ravetch, Jeffrey V (2017) Fc? Receptor Function and the Design of Vaccination Strategies. Immunity 47:224-233

Showing the most recent 10 out of 52 publications